Contemporary management and control of uncomplicated hypertension in Canada: Insight from the primary care audit of global risk management (PARADIGM) Study

Canadian Journal of Cardiology

Volumn 31, Issue 5, 2015, Pages 664-670

  Gupta, Milan ^a,b,c   Szmitko, Paul ^d,e   Singh, Narendra ^a,f   Tsigoulis, Michelle ^a   Kajil, Mahesh ^a   Stone, James ^g  

^a Canadian Cardiovascular Research Network   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d HUMBER RIVER REGIONAL HOSPITAL   (Canada)

^e SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^f MEDICAL COLLEGE OF GEORGIA   (United States)

^g UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ANTIHYPERTENSIVE AGENT;

ABDOMINAL OBESITY; ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE REGULATION; CANADA; CANADIAN; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DYSLIPIDEMIA; FEMALE; FRAMINGHAM RISK SCORE; HIGH RISK PATIENT; HUMAN; HYPERTENSION; INTERMEDIATE RISK PATIENT; LOW RISK PATIENT; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MIDDLE AGED; MONOTHERAPY; PRESCRIPTION; SMOKING; SYSTOLIC BLOOD PRESSURE; AGED; BLOOD PRESSURE; BLOOD PRESSURE MEASUREMENT; COHORT ANALYSIS; COMPARATIVE STUDY; DRUG COMBINATION; DRUG EFFECTS; FOLLOW UP; HEALTH; MEDICAL AUDIT; PROCEDURES; REFERENCE VALUE; RISK MANAGEMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

AGED; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BLOOD PRESSURE DETERMINATION; CANADA; COHORT STUDIES; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GLOBAL HEALTH; HUMANS; HYPERTENSION; MALE; MEDICAL AUDIT; MIDDLE AGED; REFERENCE VALUES; RISK MANAGEMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84928822014     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2015.03.012     Document Type: Article

References (18)

1. Lim S.S., Vos T., Flaxman A.D., et al. Acomparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012, 380:2224-2260.
2. McAlister F.A., Herman R.J., Khan N.A., et al. Putting ACCOMPLISH into context: management of hypertension in 2010. CMAJ 2010, 182:1600-1601.
3. Robitaille C., Dai S., Waters C., et al. Diagnosed hypertension in Canada: incidence, prevalence and associated mortality. CMAJ 2012, 184:E49-E56.
4. Law M.R., Morris J.K., Wald N.J. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009, 338:b1665.
5. Blood Pressure Lowering Treatment Trialists' Collaboration, Turnbull F., Neal B., et al. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. BMJ 2008, 336:1121-1123.
6. Campbell N.R., Brant R., Johansen H., et al. Increases in antihypertensive prescriptions and reductions in cardiovascular events in Canada. Hypertension 2009, 53:128-134.
7. Leenen F.H., Dumais J., McInnis N.H., et al. Results of the Ontario survey on the prevalence and control of hypertension. CMAJ 2008, 178:1441-1449.
8. Wang Y.R., Alexander G.C., Stafford R.S. Outpatient hypertension treatment, treatment intensification, and control in Western Europe and the United States. Arch Intern Med 2007, 167:141-147.
9. Hypertension Canada. Canadian Hypertension Education Program (CHEP) Recommendations. Available at:. Accessed May 5, 2009. http://www.hypertension.ca/en/chep.
10. Gee M.E., Campbell N.R., Gwadry-Sridhar F., et al. Antihypertensive medication use, adherence, stops, and starts in Canadians with hypertension. Can J Cardiol 2012, 28:383-389.
11. McAlister F.A., Wilkins K., Joffres M., et al. Changes in the rates of awareness, treatment and control of hypertension in Canada over the past two decades. CMAJ 2011, 183:1007-1013.
12. Walker R.L., Chen G., Campbell N.R., et al. Canadian provincial trends in antihypertensive drug prescriptions between 1996 and 2006. Can J Cardiol 2011, 27:461-467.
13. Dasgupta K., Quinn R.R., Zarnke K.B., et al. The 2014 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. Can J Cardiol 2014, 30:485-501.
14. Jamerson K., Weber M.A., Bakris G.L., et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. NEngl J Med 2008, 359:2417-2428.
15. Nguyen T., Lau D.C. The obesity epidemic and its impact on hypertension. Can J Cardiol 2012, 28:326-333.
16. Finucane M.M., Stevens G.A., Cowan M.J., et al. National, regional, and global trends in body mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants. Lancet 2011, 377:557-567.
17. Sim J.J., Handler J., Jacobsen S.J., et al. Systemic implementation strategies to improve hypertension: the Kaiser Permanente Southern California experience. Can J Cardiol 2014, 30:544-552.
18. Allen J.K., Dennison-Himmelfarb C.R., Szanton S.L., et al. Community Outreach and Cardiovascular Health (COACH) Trial: a randomized, controlled trial of nurse practitioner/community health worker cardiovascular disease risk reduction in urban community health centers. Circ Cardiovasc Qual Outcomes 2011, 4:595-602.